Site-specific heterogeneity in treatment response among patients with metastatic bladder cancer: implications for oligometastatic disease—a retrospective cohort study

Description

Tianwei Wang and Bingjian Wei asked in 2026 whether where bladder cancer spreads changes what treatment can achieve, using a United States registry linked to insurance claims. Their dataset held 105,554 patients diagnosed between 2000 and 2021. The question matters because the label oligometastatic, meaning limited spread, decides who gets extra local therapy.

Spread to bone, brain, liver, or lung each carried a strong survival penalty, while distant lymph node spread alone did not. Chemotherapy helped at every site, and broader systemic therapy helped everywhere except the brain. Radiation added survival benefit only for bone and liver deposits. Operating on distant deposits never helped, and removing distant lymph nodes actually tracked with shorter survival. The authors argue the metastatic site belongs inside any future definition of limited spread. Lumping all sites together, their data suggest, misleads treatment planning.

Catalog record

Source: https://europepmc.org/articles/PMC13263882